319 related articles for article (PubMed ID: 29621274)
41. Nationwide screening for Fabry disease in unselected stroke patients.
Tomek A; Petra R; Paulasová Schwabová J; Olšerová A; Škorňa M; Nevšímalová M; Šimůnek L; Herzig R; Fafejtová Š; Mikulenka P; Táboříková A; Neumann J; Brzezny R; Sobolová H; Bartoník J; Václavík D; Vachová M; Bechyně K; Havlíková H; Prax T; Šaňák D; Černíková I; Ondečková I; Procházka P; Rajner J; Škoda M; Novák J; Škoda O; Bar M; Mikulík R; Dostálová G; Linhart A;
PLoS One; 2021; 16(12):e0260601. PubMed ID: 34905550
[TBL] [Abstract][Full Text] [Related]
42. A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3).
Perrone A; Mohamed S; Donadio V; Liguori R; Contin M
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885938
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive clinical evaluation of a large Spanish family with Anderson-Fabry disease, novel GLA mutation and severe cardiac phenotype.
San Román-Monserrat I; Moreno-Flores V; López-Cuenca D; Rodríguez-González-Herrero E; Guillén-Navarro E; Rodríguez-González-Herrero B; Alegría-Fernández M; Poza-Cisneros G; Piñero-Fernández JA; Sornichero-Martínez J; Gimeno-Blanes JR
Med Clin (Barc); 2014 Jun; 142(11):497-504. PubMed ID: 24679964
[TBL] [Abstract][Full Text] [Related]
45. Fabry Disease in Families With Hypertrophic Cardiomyopathy: Clinical Manifestations in the Classic and Later-Onset Phenotypes.
Adalsteinsdottir B; Palsson R; Desnick RJ; Gardarsdottir M; Teekakirikul P; Maron M; Appelbaum E; Neisius U; Maron BJ; Burke MA; Chen B; Pagant S; Madsen CV; Danielsen R; Arngrimsson R; Feldt-Rasmussen U; Seidman JG; Seidman CE; Gunnarsson GT
Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28798024
[TBL] [Abstract][Full Text] [Related]
46. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
[TBL] [Abstract][Full Text] [Related]
47. [Screening Test of Fabry Disease in Patients with Renal Replacement Therapy in the City of Modena].
Alfano G; Ganda N; Cerami C; Mori G; Fontana F; Cappelli G
G Ital Nefrol; 2018 Mar; 35(2):. PubMed ID: 29582965
[TBL] [Abstract][Full Text] [Related]
48. Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation.
Auray-Blais C; Lavoie P; Boutin M; Ntwari A; Hsu TR; Huang CK; Niu DM
Clin Chim Acta; 2017 Mar; 466():185-193. PubMed ID: 28108302
[TBL] [Abstract][Full Text] [Related]
49. Accuracy diagnosis improvement of Fabry disease from dried blood spots: Enzyme activity, lyso-Gb3 accumulation and GLA gene sequencing.
Delarosa-Rodríguez R; Santotoribio JD; Paula HA; González-Meneses A; García-Morillo S; Jiménez-Arriscado P; Guerrero JM; Macher HC
Clin Genet; 2021 Jun; 99(6):761-771. PubMed ID: 33527381
[TBL] [Abstract][Full Text] [Related]
50. Enzyme replacement therapy improves cardiac features and severity of Fabry disease.
Motwani M; Banypersad S; Woolfson P; Waldek S
Mol Genet Metab; 2012 Sep; 107(1-2):197-202. PubMed ID: 22704481
[TBL] [Abstract][Full Text] [Related]
51. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.
Vedder AC; Linthorst GE; van Breemen MJ; Groener JE; Bemelman FJ; Strijland A; Mannens MM; Aerts JM; Hollak CE
J Inherit Metab Dis; 2007 Feb; 30(1):68-78. PubMed ID: 17206462
[TBL] [Abstract][Full Text] [Related]
52. Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.
Parini R; Pintos-Morell G; Hennermann JB; Hsu TR; Karabul N; Kalampoki V; Gurevich A; Ramaswami U;
Drug Des Devel Ther; 2020; 14():2149-2158. PubMed ID: 32581513
[TBL] [Abstract][Full Text] [Related]
53. Usefulness of lyso-globotriaosylsphingosine in dried blood spots in the differential diagnosis between multiple sclerosis and Anderson-Fabry's disease.
Olivera S; Iñiguez C; García-Fernández L; Sierra JL; Camón AM; Menao S; Torralba MÁ
Mult Scler Relat Disord; 2020 Feb; 38():101466. PubMed ID: 31715500
[TBL] [Abstract][Full Text] [Related]
54. Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.
Tuttolomondo A; Baglio I; Riolo R; Todaro F; Parrinello G; Miceli S; Simonetta I
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203231
[TBL] [Abstract][Full Text] [Related]
55. Is globotriaosylceramide a useful biomarker in Fabry disease?
Young E; Mills K; Morris P; Vellodi A; Lee P; Waldek S; Winchester B
Acta Paediatr Suppl; 2005 Mar; 94(447):51-4; discussion 37-8. PubMed ID: 15895713
[TBL] [Abstract][Full Text] [Related]
56. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.
Nowak A; Mechtler TP; Hornemann T; Gawinecka J; Theswet E; Hilz MJ; Kasper DC
Mol Genet Metab; 2018 Feb; 123(2):148-153. PubMed ID: 28728877
[TBL] [Abstract][Full Text] [Related]
57. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
[TBL] [Abstract][Full Text] [Related]
58. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study.
Germain DP; Brand E; Burlina A; Cecchi F; Garman SC; Kempf J; Laney DA; Linhart A; Maródi L; Nicholls K; Ortiz A; Pieruzzi F; Shankar SP; Waldek S; Wanner C; Jovanovic A
Mol Genet Genomic Med; 2018 Apr; 6(4):492-503. PubMed ID: 29649853
[TBL] [Abstract][Full Text] [Related]
59. Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease.
Nose Y; Fujii H; Goto S; Kono K; Okamoto H; Watanabe K; Nishi S
Mol Genet Metab; 2023 Aug; 139(4):107634. PubMed ID: 37406430
[TBL] [Abstract][Full Text] [Related]
60. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
